Anti-obesity drugs, also known as weight-loss medications, are prescribed as a part of a comprehensive weight-loss program that includes lifestyle modifications, such as dietary changes and increased physical activities. They are intended for individuals with a body mass index (BMI) above a certain threshold or those with obesity-related health conditions. They are typically prescribed under the supervision of healthcare professionals and are not intended for cosmetic weight loss purposes. As they assist in reducing feelings of hunger, promoting satiety, absorbing fat, and increasing metabolism, the demand for anti-obesity drugs is increasing around the world.

How Big is the Global Anti-Obesity Drugs Market? 

The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.

Global Anti-Obesity Drugs Market Trends:

At present, the growing rate of obesity among the masses due to changing lifestyles and decreasing exercise practices represents one of the major key factors influencing the market positively.

In addition, the rising awareness about healthy lifestyles among individuals is providing lucrative growth opportunities to industry investors. Besides this, key players are investing in research and development (R&D) activities to introduce drugs that can counter both obesity and type 2 diabetes. Moreover, the rising intake of junk food and fast food products among youngsters is propelling the growth of the market.

Apart from this, the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings is strengthening the growth of the market.

Download your free sample brochure:  https://www.imarcgroup.com/anti-obesity-drugs-market/requestsample

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including: 

Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Browse Other Reports:

Population Health Management Market Size Reach US$ 194.3 Billion by 2028

Global Clinical Trial Management Systems Market Size Reach US$ 1,953.4 Million by 2028

Gene Therapy Market Size Reach US$ 10.9 Billion by 2028

Global Dental 3D Printing Market Size US$ 5.6 Billion by 2028

Global Interventional Cardiology Devices Market Size US$ 33.8 Billion by 2028

Tags:

See Campaign: https://bit.ly/43ORZSW

Contact Information:

IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA USA: +1-631-791-1145 | Asia: +91-120-433-0800 Email: [email protected] Follow us on Twitter: @imarcglobal LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/

Tags:
IPS, Extended Distribution, iCN Internal Distribution, Research Newswire, English